Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).

被引：0

作者：

Ozguroglu, Mustafa ^{[1
]}

Alva, Ajjai Shivaram ^{[2
]}

Csoszi, Tibor ^{[3
]}

Matsubara, Nobuaki ^{[4
]}

Geczi, Lajos ^{[5
]}

Cheng, Susanna Y. ^{[6
]}

Fradet, Yves ^{[7
]}

Oudard, Stephane ^{[8
]}

Vulsteke, Christof ^{[9
]}

Morales-Barrera, Rafael ^{[10
]}

Flechon, Aude ^{[11
]}

Gunduz, Seyda ^{[12
]}

Loriot, Yohann ^{[13
]}

Rodriguez-Vida, Alejo ^{[14
]}

Mamtani, Ronac ^{[15
]}

Yu, Evan Y. ^{[16
]}

Nam, Kijoeng ^{[17
]}

Imai, Kentaro ^{[17
]}

Moreno, Blanca Homet ^{[17
]}

Powles, Thomas ^{[18
]}

机构：

[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey

[2] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[3] Hetenyi G Korhaz, Szolnok, Hungary

[4] Natl Canc Ctr Hosp East, Div Breast & Med Oncol, Chiba, Japan

[5] Natl Inst Oncol, Budapest, Hungary

[6] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[7] Univ Laval, CHU Quebec, Quebec City, PQ, Canada

[8] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Oncol, Paris, France

[9] Univ Antwerp, Integrated Canc Ctr Ghent, Ctr Oncol Res CORE, Ghent, Belgium

[10] Vall dHebron Inst Oncol, Barcelona, Spain

[11] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[12] Akdeniz Univ, Antalya, Turkey

[13] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[14] Hosp del Mar Res Inst, Dept Med Oncol, Barcelona, Spain

[15] Univ Penn, Philadelphia, PA 19104 USA

[16] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Queen Mary Univ London, Barts Canc Inst, Barts Expt Canc Med Ctr, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.448

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448

引用

页数：4

共 50 条

[21] Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Wu, Y-L.
Zhang, L.
Fan, Y.
Zhou, J.
Zhang, L.
Zhou, Q.
Li, W.
Hu, C.
Chen, G.
Zhang, X.
Zhou, C.
Souza, F.
Lin, J.
Wang, J.
Li, B.
Mok, T.
ANNALS OF ONCOLOGY, 2020, 31 : S1394 - S1394
[22] KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
Gadgeel, S.
Rodriguez-Abreu, D.
Felip, E.
Esteban, E.
Speranza, G.
Reck, M.
Hui, R.
Boyer, M.
Garon, E. B.
Horinouchi, H.
Cristescu, R.
Aurora-Garg, D.
Lunceford, J.
Kobie, J.
Ayers, M.
Piperdi, B.
Pietanza, M. C.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2019, 30 : 64 - 65
[23] Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Satake, Hironaga
Lee, Keun Wook
Chung, Hyun Cheol
Lee, Jeeyuan
Yamaguchi, Kensei
Chen, Jen-Shi
Yoshikawa, Takaki
Amagai, Kenji
Yeh, Kun-Huei
Goto, Masahiro
Chao, Yee
Lam, Ka-On
Han, Shi Rong
Shiratori, Shinichi
Shah, Sukrut
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Health-related quality of life (HRQoL) with pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355
Cescon, D. W.
Schmid, P.
Rugo, H. S.
Im, S-A.
Yusof, M. Md
Gallardo, C. E.
Lipatov, O.
Barrios, C. H.
Perez Garcia, J. M.
Iwata, H.
Masuda, N.
Torregroza Otero, M. A.
Gokmen, E.
Loi, S.
Haiderali, A.
Zhou, X.
Guo, Z.
Nguyen, A. Martin
Cortes, J.
ANNALS OF ONCOLOGY, 2022, 33 : S197 - S198
[25] Response to firstline (1L) pembrolizumab (pembro) plus chemotherapy (chemo) in nonsmall cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial
Bar, Jair
Esteban, Emilio
Rodriguez-Abreu, Delvys
Aix, Santiago Ponce
Szalai, Zsuzsanna
Felip, Enriqueta
Gottfried, Maya
Pulla, Mariano Provencio
Robinson, Andrew
Fulop, Andrea
Rao, Suman B.
Camidge, D. Ross
Speranza, Giovanna
Townson, Steven M.
Kobie, Julie
Ayers, Mark
Dettman, Elisha J.
McDaniel, Robert
Jung, Byoungsok
Burkhardt, David
Mauntz, Ruth
Csoszi, Tibor
CANCER RESEARCH, 2023, 83 (08)
[26] Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) plus chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC
Nishio, M.
Peled, N.
Zer, A.
Houghton, B.
Bar, J.
Drew, D.
Herbst, R.
Rodriguez-Abreu, D.
Talpur, R.
Golden, L.
Yin, L.
Dang, T.
Hui, R.
ANNALS OF ONCOLOGY, 2020, 31 : S848 - S849
[27] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Rha, S. Y.
Wyrwicz, L. S.
Weber, P. E. Y.
Bai, Y.
Ryu, M. H.
Lee, J.
Rivera, F.
Alves, G. V.
Garrido, M.
Shiu, K. -k.
Fernandez, M. Gonzalez
Li, J.
Lowery, M.
Cil, T.
Cruz, F. J. S. M.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Oh, D-y.
ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
[28] Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Greil, R.
Rischin, D.
Harrington, K. J.
Soulieres, D.
Tahara, M.
de Castro, G.
Psyrri, A.
Baste, N.
Neupane, P.
Bratland, A.
Fuereder, T.
Hughes, B. G. M.
Mesia, R., Sr.
Ngamphaiboon, N.
Rordorf, T.
Ishak, W. Z. Wan
Lin, J.
Swaby, R. F.
Gumuscu, B.
Burtness, B.
ANNALS OF ONCOLOGY, 2020, 31 : S660 - S661
[29] Niraparib (Nira) plus Pembrolizumab (Pembro) versus placebo (PBO) + Pembro 1L maintenance therapy in advanced non-small cell lung cancer (NSCLC): ZEAL-1L phase 3 study
Schuler, M.
Ramalingam, S.
Arora, S.
Neibauer, Whipple M.
Zho, J.
Hazard, S.
Frenkl, T.
Stojadinovic, A.
Peters, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 170 - 171
[30] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Reck, M.
Rodr-Guez-Abreu, D.
Robinson, A. G.
Hui, R.
Csoszi, T.
Fulop, A.
Gottfried, M.
Peled, N.
Tafreshi, A.
Cuffe, S.
O'Brien, M.
Rao, S.
Hotta, K.
Leiby, M.
Lubiniecki, G. M.
Shentu, Y.
Rangwala, R.
Brahmer, J. R.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →